Finally, the mregDC phenotype was previously found to limit antitumor immunity in non-small cell lung cancer (NSCLC),96 which inspired therapeutic strategies aimed at mregDCs: blocking IL-4 signaling, combining immune checkpoint inhibitors with dendritic cell therapy based on Flt3L and α CD40.96 This evidence concerns the gene CD40 and non-small cell lung carcinoma.